Bli medlem
Bli medlem

Du är här

2019-11-12

Oncology Venture A/S: Oncology Venture reaches new development milestone with Dovitinib.

Press release

Hørsholm, Denmark 12 November 2019 ? Oncology Venture A/S (?OV? or the
?Company?) today announced that it plans to file its first NDA in 2020

As a result of the news company strategy, OV expects a strong news flow for
its three prioritized programs as the Company brings the programs further
ahead in the development in 2020.

Dovitinib
During the first half of 2020 Oncology Venture expects a pre-NDA meeting
with the US Food and Drug Administration (FDA) regarding the path to
approval for Dovitinib used to treat Renal Cell Carcinoma, (kidney cancer).
The company?s strategy is file for ?non-inferiority?, when comparing
Dovitinib with the already approved compound Sorafenib. With a successful
meeting Oncology Venture subsequent will be able to file a New Drug
Application with the FDA for the Dovitinib DPR® in the second half of 2020

Dovitinib address a significant unmet need for relevant treatments of Renal
Cell Carcinoma. Annual sales of Sorafinib, under the trade name Nexavar®,
was approximately USD 715 million in 2018. The global Renal Cell Carcinoma
market is projected to grow to USD 6.3 billon 2022.

Steve Carchedi, CEO of Oncology Ventures, ?We are excited to bring forward
our first portfolio asset utilizing the DRP toward the next step of
commercialization?. Renal Cell cancer continues to have a high unmet need
and hope that Dovitinib along with DRP will provide patients with an
effective treatment.

For further information, please contact:

Henrik Moltke, CFO
E-mail: hm@oncologyventure.com
Telephone +45 53 63 96 37

About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST)
develops drugs for personalized treatment of cancer guided by its
proprietary drug response predictor technology, DRP®. The company has a
mature portfolio of seven drug candidates, including compounds in the
pre-registration stage.
The product portfolio includes: 2X-121 a PARP inhibitor in Phase 2 for
Ovarian cancer; Dovitinib, for Renal Cell Carcinoma. Ixabepilone for the
treatment of breast cancer. LiPlaCis®, a liposomal formulation of cisplatin
in Phase 2 trial for breast and prostate cancer 2X-111, a liposomal
formulation of doxorubicin under manufacturing for Phase 2 in breast
cancer; irofulven, in Phase 2 for prostate cancer; and APO010, an
immuno-oncology product in Phase 1/2 for multiple myeloma. The Company?s
current priority program focus is for advancement of 2X-121, IXEMPRA®, and
Dovitinib.

About the Drug Response Predictor ? DRP® Companion Diagnostic
Oncology Venture uses its multi gene DRP® to select those patients who by
the genetic signature of their cancer are found to have a high likelihood
of responding to the drug. By screening patients before treatment, the
response rate can be significantly increased. The DRP® method builds on the
comparison of sensitive vs. resistant human cancer cell lines, including
genomic information from cell lines combined with clinical tumor biology.
DRP® is based on messenger RNA from the patient?s biopsies.
DRP® has proven its ability to provide a statistically significant
prediction of the clinical outcome from drug treatment in cancer patients
in 29 out of 37 clinical studies that were examined.
The DRP® platform can be used in all cancer types and is patented for more
than 70 anti-cancer drugs in the US.

Follow us on social media:
Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of OV?s control
and which could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning OV?s plans, objectives, goals, future events,
performance and/or other information that is not historical information.
All such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. OV undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.

Certified Adviser:
Svensk Kapitalmarknadsgranskning AB, Email: ca@skmg.se. Tel: +46 11 32 30
732

This information is information that Oncology Venture A/S is obliged to
make public pursuant to the EU Market Abuse Regulation. The information was
submitted for publication on November 12, 2019.

Bilaga

* Oncology Venture Release Dovitnib_November 12

Författare Hugin Nyheter

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.